“Maintenance of Response With up to 4 Years of Continuous Guselkumab Treatment: Results From the VOYAGE 1 Phase 3 Trial”. SKIN The Journal of Cutaneous Medicine, vol. 3, Nov. 2019, p. S17, https://doi.org/10.25251/skin.3.supp.17.